Modelling precise responses to anti-seizure medication using brain organoids carrying SCN2A-GoF and SCN2A-LoF mutations

Yuling Yang; Yi Yan; Yang Cai; Xin Wang; Zhicheng Shao; Jing Ding

doi:10.1002/ctm2.70666

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (4) :e70666 DOI: 10.1002/ctm2.70666

LETTER TO THE JOURNAL

Modelling precise responses to anti-seizure medication using brain organoids carrying SCN2A-GoF and SCN2A-LoF mutations

Author information +

History +

PDF (3473KB)

Cite this article

Download citation ▾

Yuling Yang, Yi Yan, Yang Cai, Xin Wang, Zhicheng Shao, Jing Ding. Modelling precise responses to anti-seizure medication using brain organoids carrying SCN2A-GoF and SCN2A-LoF mutations. Clinical and Translational Medicine, 2026, 16 (4) : e70666 DOI:10.1002/ctm2.70666

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Wolff M, Brunklaus A, Zuberi SM. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia. 2019; 60(S3): S59-S67.

[2]	Yang Y, Cai Y, Wang S, et al. Human cortical organoids with a novel SCN2A variant exhibit hyperexcitability and differential responses to anti-seizure compounds. Neurosci Bull. 2025; 41(11): 2010–2024.

[3]	Amador A, Bostick CD, Olson H, et al. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain. 2020; 143(7): 2039-2057.

[4]	Jia L, Li M, Pachernegg S, et al. Variant-specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy. J Neurochem. 2024; 168(12): 3950-3961.

[5]	Booker SA, Pires N, Cobb S, et al. Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors. Neuropharmacology. 2015; 93: 103-115.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.